NCT07428785Recruiting
Pulmonary and Total Blood Volume in COPD
Pulmonary and Total Blood Volume in COPD: A Prosoective Matched Comparative Study
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
Background Patients with chronic obstructive lung disease (COPD) suffer from a progressive loss of lung function that leads to poor quality of life, and often invalidity and early death. This is markedly affected by a reduced exercise capacity and dyspnoea, but the underlying mechanisms are unknown. In the present study, we aim to investigate whether this may involve a reduced pulmonary blood volume secondarily to a reduced total blood volume. Methods Design: Prospective matched comparative study Intervention: None Outcomes: The primary outcome is pulmonary blood volume estimated to total blood volume ratio between patients with COPD and healthy controls individually matched for age, sex, and height. Statistical design: All statistical analyses will be performed using R statistical software version 4.1.1 (R Project for Statistical Computing) within RStudio statistical software version 1.4.1717 (RStudio), and a two-tailed p\<0.05 will be considered statistically significant. Inspection of normality and variance homogeneity will be done by creating qq-plots and histogram. Regulatory considerations: This study will be submitted for approval by Regional Ethical Committee. Perspective: This study will help uncover fundamental aspects of the pathophysiology of COPD.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 32 (estimated)
- First submitted
- 1 Dec 2025
- Start date
- 15 Sept 2025
- Primary completion date
- 20 Dec 2026
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Diseases
- COPD
- NCT number
- NCT07428785
What you commit to
- Study type: Observational
- Planned participants: 32
- From 15 Sept 2025 to the primary completion date, 20 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous severe or current COVID-19
- Symptoms of disease within 2 weeks prior to the study
- Previous severe or current COVID-19
- Symptoms of disease within 2 weeks prior to the study
Other illness
- Symptoms of ischaemic heart disease
- Known heart failure
- Known malignant disease
- Unstable cardiac arrhythmic disease
- Known chronic lung disease
- Known ischaemic heart disease
- Known heart failure
- Known malignant disease
- Unstable cardiac arrhythmic disease
Other
- Claudication
- Participation in pulmonary rehabilitation within 6 months
- Pregnancy
- Renal or liver dysfunction
- Claudication
- Pregnancy
- Renal or liver dysfunction
Who the study is looking for
- Inclusion criteria -patients
- Men and women
- 45-80 years
- COPD (GOLD stage I to III)
- Resting arterial oxygenation \> 90% Inclusion criteria - controls
- Men and women
- 45-80 years
- Normal FEV1, FVC, FEV1/FVC, and single-breath diffusion capacity
- Same sex, age (± 3 years) and height (± 5 cm) as an included COPD patient
- Low- to moderate activity level defined as \< 1,5 hours of structured physical activity pr. week at moderate intensity and cycling \< 30 minutes/5km pr. day at moderate intensity (moderate intensity = out of breath but able to speak)
Age in the registry: 45 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Aktiv Sundhed Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.